APIM Therapeutics has already raised more than EUR 23M from public and private sources since 2010. Current major investors in the company include: Sarsia Seed, Norsk Innovasjonskapital III AS, Trond Mohn Stiftelse, Investinor AS and Birk Venture. The procceeds of the latest financing round are currently used to pursue further clinical development of ATX-101. For more information on potential investments, feel free to contact us.